Significantly Better Prognosis for Patients with Primary Plasma Cell Leukemia than for Patients with Secondary Plasma Cell Leukemia
- 1 October 2007
- journal article
- research article
- Published by S. Karger AG in Acta Haematologica
- Vol. 118 (3), 178-182
- https://doi.org/10.1159/000109470
Abstract
Plasma cell leukemia (PCL) is a rare variant of multiple myeloma (MM). Patients may either present de novo (primary PCL), or PCL may occur during the course of MM (secondary PCL). We compared the laboratory and clinical findings of both primary and secondary PCL and MM to elucidate their natural history and the relationship among these entities. Ten cases of PCL (7 cases of primary PCL and 3 cases of secondary PCL) and 20 sex- and age-matched cases of MM were compared. The patients with primary PCL showed significantly lower platelet and neutrophil counts in peripheral blood and higher cellularity in bone marrow than patients with MM (p = 0.002, < 0.001 and 0.027, respectively). Immunophenotypic studies showed a different expression of HLA-DR and CD117 antigens among the 3 groups. There was a significant difference in survival between the 3 groups (median survival of primary PCL, secondary PCL and MM = 22.2, 1.3 and 36.4 months, respectively; p = 0.048). The patients with primary PCL showed better prognosis than those with secondary PCL. Primary PCL might be a differently developed disease from MM. In diagnosing PCL, it is important to differentiate primary PCL from secondary PCL for the prediction of prognosis.Keywords
This publication has 12 references indexed in Scilit:
- Primary plasma cell leukemia: Report of 17 new cases treated with autologous or allogeneic stem‐cell transplantation and review of the literatureAmerican Journal of Hematology, 2005
- Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemiaAnnals of Hematology, 2002
- Clinicopathological and prognostic characteristics of CD56‐negative multiple myelomaBritish Journal of Haematology, 2002
- Primary plasma cell leukaemia: a report of 18 casesLeukemia Research, 2001
- The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myelomaLeukemia, 1998
- Primary plasma cell leukaemiaBritish Journal of Haematology, 1994
- Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cellsBlood, 1994
- Cell Surface Markers in Multiple MyelomaMayo Clinic Proceedings, 1994
- Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the diseaseBritish Journal of Haematology, 1991
- Plasma cell leukemia: An evaluation of response to therapyAmerican Journal Of Medicine, 1987